134 related articles for article (PubMed ID: 20947804)
1. Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women.
Tawfik O; Davis K; Kimler BF; Davis MK; Hull S; Fan F; Khan QJ; O'Dea AP; Thomas P
Ann Clin Lab Sci; 2010; 40(4):315-23. PubMed ID: 20947804
[TBL] [Abstract][Full Text] [Related]
2. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.
Ugras S; Stempel M; Patil S; Morrow M
Ann Surg Oncol; 2014 Nov; 21(12):3780-6. PubMed ID: 24952028
[TBL] [Abstract][Full Text] [Related]
4. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
5. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome.
Sullivan HC; Oprea-Ilies G; Adams AL; Page AJ; Kim S; Wang J; Cohen C
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):17-23. PubMed ID: 23455177
[TBL] [Abstract][Full Text] [Related]
7. Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival.
Oprea-Ilies G; Haus E; Sackett-Lundeen L; Liu Y; McLendon L; Busch R; Adams A; Cohen C
Breast Cancer Res Treat; 2013 Feb; 137(3):677-87. PubMed ID: 23250547
[TBL] [Abstract][Full Text] [Related]
8. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.
Jones BA; Kasl SV; Howe CL; Lachman M; Dubrow R; Curnen MM; Soler-Vila H; Beeghly A; Duan F; Owens P
Cancer; 2004 Sep; 101(6):1293-301. PubMed ID: 15368321
[TBL] [Abstract][Full Text] [Related]
9. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Elledge RM; Clark GM; Chamness GC; Osborne CK
J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of HER-2/NEU receptor of invasive mammary carcinoma between Caucasian and African American patients in the Detroit metropolitan area. Correlation with overall survival and other prognostic factors.
Al-Abbadi MA; Washington TA; Saleh HA; Tekyi-Mensah SE; Lucas DR; Briston CA
Breast Cancer Res Treat; 2006 May; 97(1):3-8. PubMed ID: 16432664
[TBL] [Abstract][Full Text] [Related]
11. Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer.
Tan F; Mosunjac M; Adams AL; Adade B; Taye O; Hu Y; Rizzo M; Ofori-Acquah SF
BMC Cancer; 2014 Sep; 14():715. PubMed ID: 25255861
[TBL] [Abstract][Full Text] [Related]
12. p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
[TBL] [Abstract][Full Text] [Related]
13. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
14. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases.
Megha T; Neri A; Malagnino V; Caruso S; Onorati M; Roviello F; Tosi P
Cancer Biol Ther; 2010 Feb; 9(4):266-73. PubMed ID: 20026902
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases].
Guan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):196-9. PubMed ID: 18756935
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
20. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium.
Bandera EV; Chandran U; Hong CC; Troester MA; Bethea TN; Adams-Campbell LL; Haiman CA; Park SY; Olshan AF; Ambrosone CB; Palmer JR; Rosenberg L
Breast Cancer Res Treat; 2015 Apr; 150(3):655-66. PubMed ID: 25809092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
